The Clinical Characteristics of Patients With Pyoderma Gangrenosum in a Tertiary Referral Hospital: A Retrospective Cohort Study.

Since pyoderma gangrenosum (PG) is a rare neutrophilic dermatosis, epidemiological and clinical data on the disease are scarce. In this single-center retrospective study, we aim to evaluate the clinical characteristics, underlying systemic associations and treatment modalities in patients with PG in...

Descripción completa

Detalles Bibliográficos
Publicado en:International Journal of Lower Extremity Wounds Vol. 25; no. 1; pp. 150 - 155
Autores principales: Afacan Yıldırım, Elif, Can Edek, Yusuf, Adısen, Esra
Formato: pictorial research tables/charts Journal Article
Publicado: Sage Publications Inc. Mar2026
Acceso en línea:Ver este registro en EBSCOhost
fields @attributes:
  recordID: 1
pdfLink:
plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=191330948&site=ehost-live
header:
  @attributes:
    shortDbName: ccm
    uiTerm: 191330948
    longDbName: CINAHL Complete
    uiTag: AN
  controlInfo:
    bkinfo:
    dissinfo:
    jinfo:
      jid:
        15347346
        IYG
      jtl: International Journal of Lower Extremity Wounds
      issn: 15347346
      maglogo: Y
    pubinfo:
      dt: Mar2026
      vid: 25
      iid: 1
      pid: 344
      pub: Sage Publications Inc.
      place: Thousand Oaks, California
    artinfo:
      ui:
        191330948
        171911738
        191330948
        191330948
        10.1177/15347346231196957
        191330948
      ppf: 150
      ppct: 5
      formats:
      tig:
        atl: The Clinical Characteristics of Patients With Pyoderma Gangrenosum in a Tertiary Referral Hospital: A Retrospective Cohort Study.
      aug:
        au:
          Afacan Yıldırım, Elif
          Can Edek, Yusuf
          Adısen, Esra
        affil: Faculty of Medicine, Department of Dermatology, Demiroglu Bilim University, Istanbul, Turkey
      sug:
        subj:
          Pyoderma Gangrenosum
          Disease Attributes
          Tertiary Health Care
          Human
          Male
          Female
          Adult
          Middle Age
          Aged
          Aged, 80 and Over
          Retrospective Design
          Record Review
          Descriptive Statistics
          Data Analysis Software
          Pearson's Correlation Coefficient
          Chi Square Test
          Age Factors
          Sex Factors
          Lower Extremity Pathology
          Recurrence
          Medication Compliance
          Wound Care
          Adult: 19-44 years
          Middle Aged: 45-64 years
          Aged: 65+ years
          Aged, 80 & over
          Male
          Female
      ab: Since pyoderma gangrenosum (PG) is a rare neutrophilic dermatosis, epidemiological and clinical data on the disease are scarce. In this single-center retrospective study, we aim to evaluate the clinical characteristics, underlying systemic associations and treatment modalities in patients with PG in a university hospital between 2014 and 2022. It is known that PG most commonly affects the lower extremities, but extracutaneous involvement should also be kept in mind. PG is usually associated with various comorbidities that share a similar inflammatory pathogenesis with the disease. The prevalence of PG-related comorbidities varies in different studies, arthritis and solid organ malignancies were observed most frequently in the current study. Non-PG-related comorbidities including diabetes mellitus, hypertension and peripheral vascular disease can adversely affect wound healing and limit treatment options; therefore, a holistic approach to patients with PG is crucial. Consistent with literature, the mainstay of treatment for PG is systemic corticosteroids and cyclosporine. However, the implementation of biologic agents in treatment-resistant patients is an increasingly important issue in the literature. Antitumor necrosis factors (anti-TNFs) are the most commonly preferred biological therapies, and these agents seem to have paved the way for a paradigm shift in the treatment of PG. In the present study, a relatively high per cent of (23.3%) patients treated with anti-TNFs, most commonly infliximab (87.5%). Recurrence was observed in 46.7% of our patients in the follow-up period and the relapse rate was found to be higher in patients using multiple systemic agents compared to those using single agents (64.7% vs 23.1%, P <.05). In conclusion, we emphasize that early diagnosis and treatment by considering the patient's comorbidities are important in preventing complications, and biologic treatments seem particularly promising in treatment-resistant patients.
      pubtype: Academic Journal
      doctype:
        pictorial
        research
        tables/charts
        Journal Article
      ougenre: Article
    language: English
    refInfo:
    holdings:
      @attributes:
        islocal: N